GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients. [electronic resource]
Producer: 20110308Description: 117-26 p. digitalISSN:- 1521-7035
- Adolescent
- Alum Compounds -- administration & dosage
- Autoantibodies -- blood
- CD4-Positive T-Lymphocytes -- cytology
- Cell Count
- Child
- Diabetes Mellitus, Type 1 -- enzymology
- Female
- Forkhead Transcription Factors -- genetics
- Gene Expression -- genetics
- Glutamate Decarboxylase -- administration & dosage
- Humans
- Immunosuppression Therapy -- methods
- Interferon-gamma -- metabolism
- Interleukin-2 Receptor alpha Subunit -- metabolism
- Interleukins -- metabolism
- Leukocytes, Mononuclear -- cytology
- Lymphocyte Activation -- immunology
- Male
- T-Lymphocytes, Regulatory -- cytology
- Th2 Cells -- immunology
- Transforming Growth Factor beta -- genetics
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- metabolism
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.